ColemanR.E.: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev2001; 27: 165–176.
2.
CentenoC., SanzA., VaraF.: Bone metastasis: clinical manifestations and complications. A cross-disciplinary treatment. Med Pal2001; 8: 100–108.
3.
MirelsH.: Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathological fractures. Clin Orthop Rel Res1989; 249: 256–264.
4.
RosenL.S., GordonD., KaminskiM.: Zoledronic acid vs pamidronate in the treatment of skeletal metastasis in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001; 7(5): 377–387.
5.
HillnerB.E., IngleJ.N., ChlebowskiR.T.: ASCO 2003 update on the role of bisphosphonates and bone health issue in women with breast cancer. J Clin Oncol2003; 21: 4042–4057.
6.
MuhlbauerR.C., BaussF., SchenkR.: BM 210955: a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res1991; 6: 1003–1011.
7.
RalstonS.H., ThiebaudD., HermannZ.: Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer1997; 75: 295–300.
8.
PecherstorferM., SteinhauerE.U., RizzoliR.: Efficacy and safety of ibandronate in the treatment of hypercalcaemia of malignancy: a randomised multicentric comparison to pamidronate. Support Care Cancer2003; 11: 539–547.
9.
BodyJ.J., DielI.J., LichinitserM.R.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol2003; 14: 1399–1405.
10.
TripathyD., BodyJ.J., DielI.: Oral daily ibandronate: efficacy in reducing skeletal complications in patients with metastatic bone disease from breast cancer. Proc ASCO2003; 22: 46 (A 185).
11.
BodyJ.J., KanisJ., DielI.: Risk reductions in metastatic breast cancer: multivariate Poisson regression analysis of oral and iv ibandronate. Proc ASCO2003; 22: 46 (A 184).
12.
ManciniI., DumanJ.C., TothC.: Short-term treatment with the bisphosphonate ibandronate for opioid-resistant metastatic bone pain. Bone2002; 30 (Suppl 3): 51 (A 56).
13.
HeidenreichA., OhlmannC., OlbertP.: High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Presented at ECCO 12, Copenhagen (Denmark), 21-25 September 2003.
14.
NeugebauerG., KohlerW., AkinkunmiL.: Influence of peak ibandronic acid concentrations after 6 mg iv administration with shortened infusion time (15 abd 30 minutes) on renal safety in man. Proc ASCO2001; 20(A 486).
